Companies /Healthcare

AKTS

AKTS Biotechnology

$25.91

▲ $0.13 (+0.50%) today

Markets closed · 9:46pm ET

Today · % change

Fundamentals

Market Cap

$1.4B

Revenue (TTM)

$10.1M

EPS (TTM)

$-1.30

52-Week Range

$15 – $34

Street Target

$34.81

About AKTS

Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures and sells radio frequency (RF) filter products for the wireless mobile device industry in the United States. The company is headquartered in Huntersville, North Carolina.

AKTS Coverage

8:10am ET

Investing

Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play

A clinical-stage radiopharmaceutical startup with no product revenue just caught the attention of three of pharma's biggest acquirers, and the rights structure hiding inside its Lilly partnership may explain exactly why.

AKTS BMY LLY

Trey Thoelcke

8:45am ET

Investing

Huge Insider Buying Now at This Insurance Giant and 2 Biotechs

Alumis, Aktis Oncology, and W.R. Berkley saw the most prominent insider buying of the past week. There were a handful of other notable purchases as well.

AKTS ALMS HYMC

Trey Thoelcke